2020 Volume 37 Issue 5 Pages 744-746
Various clinical trials for peripheral neuropathy were published in 2019. Systematic review was performed using terms, “neuropathy”, “peripheral neuropathy”, “treatment” and “clinical trials” with the time lock from January 1, 2019 through December 31, 2019. A total of 19 trials were reviewed in this article on diabetic neuropathy (DPN ; n＝7), chemotherapy–induced peripheral neuropathy (CIPN ; n＝5), carpal tunnel syndrome (n＝4), hereditary ATTR amyloidosis (n＝1), chronic inflammatory demyelinating polyneuropathy (CIDP ; n＝1), and multifocal motor neuropathy (n＝1). For painful DPN, milogabalin, exercise, curcumin, deep tissue laser stimulation, and bio–feedback were found to be effective for pain relief. For CIPN, efficacy of pregabalin and duloxetine was confirmed, but muscle stimulatyion, cryotherapy, and topical agents did not show significant efficacy. For ATTR amyloidosis, a tolcapone trial revealed a short–term efficacy on TTR stabilization. For immune–mediated neuropathies, subcutaneous immunoglobulin as a maintenance therapy for CIDP, and multifocal motor neuropath were published. These results showed sustained research activity to develop new therapies for a number of peripheral nerve disorders.
